CDK4/6-IN-2

CAS No. 1800506-48-2

CDK4/6-IN-2( —— )

Catalog No. M23813 CAS No. 1800506-48-2

CDK4/6-IN-2 is a potent CDK4 and CDK6 inhibitor (IC50s: 2.7 and 16 nM) extracted from patent US20180000819A1 (Compound 1).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 151 In Stock
5MG 258 In Stock
10MG 410 In Stock
25MG 678 In Stock
50MG 954 In Stock
100MG 1287 In Stock
500MG 2574 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    CDK4/6-IN-2
  • Note
    Research use only, not for human use.
  • Brief Description
    CDK4/6-IN-2 is a potent CDK4 and CDK6 inhibitor (IC50s: 2.7 and 16 nM) extracted from patent US20180000819A1 (Compound 1).
  • Description
    CDK4/6-IN-2 is a potent CDK4 and CDK6 inhibitor (IC50s: 2.7 and 16 nM) extracted from patent US20180000819A1 (Compound 1).
  • In Vitro
    CDK4/6-IN-2 inhibits H358, H441, PC3, MV-4-11, JeKo-1, SW780, and HGC-27 cells with IC50s of 290.9, 147.8, 260.5, 139, 36.98, 162.5, and 316.4 nM, respectively.
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    CDK
  • Recptor
    CDK4|CDK6
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1800506-48-2
  • Formula Weight
    506.59
  • Molecular Formula
    C27H32F2N8
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:5mg/mL (9.87 mM; Need ultrasonic)
  • SMILES
    CC(N1C2=CC(C3=CC(NC4=NC=C(CN5CCN(CC)CC5)C=N4)=NC=C3F)=CC(F)=C2N=C1C)C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Frank Wu, et al. Kinase inhibitor and use thereof. US20180000819A1.
molnova catalog
related products
  • BQU57

    BQU57 shows selective inhibition for Ral relative to Ras or Rho and inhibit xenograft tumor growth.

  • TCS 1102

    TCS 1102 is an effective, dual orexin receptor antagonist (Ki: 0.2/3 nM for OX2/1 receptors).

  • M2I-1

    The first small molecule Mad2 inhibitor that targets the binding of Mad2 to Cdc20; equally potent in inhibiting the binding of F-Mbp1 to Mad2.